Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine crossover study for cognitive symptoms in Parkinson's disease
ACTRN12625000307404Phase 2Not yet recruiting
- Sponsor
- Macquarie University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guanfacine in Parkinson's disease (PD) (2 arms), sponsored by Macquarie University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
guanfacine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ACTRN12625000307404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000307404.